High-density lipoprotein: a potent inhibitor of inflammation
- PMID: 19930423
- DOI: 10.1111/j.1440-1681.2009.05338.x
High-density lipoprotein: a potent inhibitor of inflammation
Abstract
1. Inflammation is an important process, driving the progression of atherosclerosis. Stemming inflammation may be a mechanism to inhibit the progression of this disease. 2. High-density lipoprotein (HDL), a particle inversely related to cardiovascular disease, has been described as having a number of anti-inflammatory functions. It has been shown that HDL inhibits endothelial inflammation in both in vitro and in vivo models, reducing the expression of key cell adhesion molecules. In addition, HDL has been shown to have an effect on the coagulation pathway by inhibiting platelet activation and reducing thrombus formation. Furthermore, by reducing the activation of leucocytes, HDL can inhibit leucocyte recruitment to the endothelium. 3. High-density lipoprotein infusion studies conducted in patients with inflammatory diseases have shown that acute treatment with HDL can effectively inhibit inflammation in vivo. Thus, HDL has been proven to be a potent inhibitor of inflammation, acting on a number of pathways, and this may suggest that HDL could be applied as an anti-inflammatory molecule for a number of diseases. 4. The present review highlights these important studies and reviews data on the anti-inflammatory effects of HDL from in vitro and in vivo studies, in both humans and animal models of atherosclerosis and inflammatory-related diseases.
Similar articles
-
The versatility of HDL: a crucial anti-inflammatory regulator.Eur J Clin Invest. 2010 Dec;40(12):1131-43. doi: 10.1111/j.1365-2362.2010.02361.x. Eur J Clin Invest. 2010. PMID: 20695882 Review.
-
High-density lipoproteins, platelets and the pathogenesis of atherosclerosis.Clin Exp Pharmacol Physiol. 2010 Jul;37(7):726-35. doi: 10.1111/j.1440-1681.2010.05377.x. Epub 2010 Mar 12. Clin Exp Pharmacol Physiol. 2010. PMID: 20337657 Review.
-
Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium.Clin Exp Pharmacol Physiol. 2010 Jul;37(7):736-42. doi: 10.1111/j.1440-1681.2010.05387.x. Epub 2010 Mar 30. Clin Exp Pharmacol Physiol. 2010. PMID: 20374256 Review.
-
High-density lipoproteins, inflammation and oxidative stress.Clin Sci (Lond). 2009 Jan;116(2):87-98. doi: 10.1042/CS20080106. Clin Sci (Lond). 2009. PMID: 19076062 Review.
-
Targeting the anti-inflammatory effects of high-density lipoprotein.Am J Cardiol. 2007 Dec 3;100(11 A):n3-9. doi: 10.1016/j.amjcard.2007.08.006. Am J Cardiol. 2007. PMID: 18047850 Review.
Cited by
-
A novel marker of persistent left ventricular systolic dysfunction in patients with peripartum cardiomyopathy: monocyte count- to- HDL cholesterol ratio.BMC Cardiovasc Disord. 2019 May 15;19(1):114. doi: 10.1186/s12872-019-1100-9. BMC Cardiovasc Disord. 2019. PMID: 31092205 Free PMC article.
-
Hypercholesterolaemia, signs of islet microangiopathy and altered angiogenesis precede onset of type 2 diabetes in the Goto-Kakizaki (GK) rat.Diabetologia. 2011 Sep;54(9):2451-62. doi: 10.1007/s00125-011-2223-4. Epub 2011 Jul 10. Diabetologia. 2011. PMID: 21744291
-
Monocyte-to-High-Density Lipoprotein Ratio Predicts the Outcome of Acute Ischemic Stroke.J Atheroscler Thromb. 2020 Sep 1;27(9):959-968. doi: 10.5551/jat.51151. Epub 2020 Jan 16. J Atheroscler Thromb. 2020. PMID: 31941849 Free PMC article.
-
Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer.Lipids Health Dis. 2016 Mar 12;15:56. doi: 10.1186/s12944-016-0225-4. Lipids Health Dis. 2016. PMID: 26970778 Free PMC article.
-
Decreased high density lipoprotein cholesterol is an independent predictor for persistent organ failure, pancreatic necrosis and mortality in acute pancreatitis.Sci Rep. 2017 Aug 14;7(1):8064. doi: 10.1038/s41598-017-06618-w. Sci Rep. 2017. PMID: 28808236 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources